Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit turns positive

Q2 FY2026 gross profit was $18.55M, compared with -$406K a year earlier. Trailing-twelve-month gross profit was $18.15M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $18.55M or moves back toward the trailing-twelve-month quarterly average of $4.54M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$18.55M+4760.3% QoQ
Last fiscal yearDec 2025
-$1.63M-2401.4% YoY
LTMJun 2026
$18.15M+2281.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4668.5%——
1 year-2401.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.63M) USD
Year-over-year change
-2401.4%

Gross Profit vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 gross profit of $18.15M is the 2nd highest of the 8 companies compared; the peer median is -$108K.
  • Its year-over-year change of +2281.5% is the 2nd highest of 7, against a peer median of -208.0%.
  • Gross profit amounts to 86.4% of revenue for HOWL, versus a peer median of 99.8%.
HOWL Competitors Peer median
Gross Profit for HOWL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$18.15M +2281.5%—86.4%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%——
INMBINmune Bio, Inc.LTM Mar 2026-$108K -316.0%-48.9%—
OSTXOS Therapies IncorporatedLTM Mar 2026-$362.39K -17280.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
ACETAdicet Bio, Inc.LTM Mar 2026-$1.34M ———
Peer median (excluding HOWL) -$108K-208.0%+65.8%99.8%

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue016.4M19.94M1.89M0
Cost of Revenue02.51M1.76M1.81M1.63M
Gross Profit013.89M18.18M71K(1.63M)
Gross Margin—84.7%91.2%3.8%—
Research & Development35.27M53.76M41.78M56.43M44.83M
Selling, General & Admin14.82M21.5M18.67M19.05M15.85M
Operating Expenses50.09M69.95M58.68M73.67M59.04M
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
EBITDA(49.77M)(52.71M)(32.47M)(64.05M)(53.91M)
EBITDA Margin—-321.4%-162.8%-3397.6%—
Operating Income(50.09M)(56.06M)(40.5M)(73.59M)(60.68M)
Operating Margin—-341.8%-203.1%-3904.2%—
Interest Income104K1.91M7.42M6.67M3.11M
Interest Expense003.14M4.66M5.27M
Other Income / Expenses104K2.25M3.14M3.08M(145K)
Income Before Tax(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Pre-Tax Margin—-328.1%-187.4%-3740.8%—
Income Tax Expense00000
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Net Margin—-328.1%-187.4%-3740.8%—
EPS (Basic)(10.94)(1.86)(1.05)(1.63)(1.32)
EPS (Diluted)(10.94)(1.86)(1.05)(1.63)(1.33)
Weighted Avg Shares18.46M28.86M35.65M43.33M46.02M
Weighted Avg Shares (Diluted)18.46M28.86M35.65M43.86M46.81M

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.